ATRC · Investment summary · as of 12 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Inflection · scaling but economically observable
The business does not meet the quality standard for its economic type.
At $42.95, ATRC requires a 16% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 14%.
The conditions that would settle the disagreement are dated to October 2026.
The value rests on an exit multiple of 14.1x, a terminal operating margin of 16% and a 8.6% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: BoxX-NoAF misses its 30-day post-operative AF endpoint at the H1 2027 readout.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Thin-margin (GAAP operating margin 2.26% TTM; negative FY2022-FY2025) BUT economically observable on all five markers: (1) 76.30% TTM gross margin, 71.6-77.2% band for ten years; (2) identifiable contribution margin - consumables into scheduled cardiac surgery; (3) visible expense scaling - TTM opex ratio down 9.1pp YoY; (4) formally guided model - FY2026 revenue $602-610m, adjusted EBITDA $85-89m, GAAP EPS $0.05-0.13 (RAISED at Q2 2026 from $0.00-0.04), plus deck-published 2028/2030 targets; (5) positive GAAP net income Q2 2026 ($9.0m). |
| What do we forecast? | Revenue growth of 14% demonstrated; a terminal operating margin of 16%; an exit multiple of 14.1x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -1.8 percentage points. |
| What is it worth? | Twelve-month target $42.19, -2% from the struck price. Scenario-weighted expected return net of costs -1.8%. |
| Why now? | The first dated test of the thesis falls on 27 October 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 27 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| H1 2027 (disclosed readout window) | Trial primary endpoint result | Neither leg of the condition opposite is met at this date | BoxX-NoAF fails its primary endpoint: no statistically significant reduction in post-operative AF at 30 days |
| 27 October 2026 | Quarterly revenue YoY | Revenue growth at or above 10% YoY for two consecutive quarters (guide is 13-14% FY2026) | Revenue growth below 10% YoY for two consecutive quarters (guide is 13-14% FY2026) |
| ~Feb 2027 | FY2026 adjusted EBITDA (issuer non-GAAP reconciliation) | FY2026 adjusted EBITDA at or above $80m - below even the pre-raise guidance floor, breaking the operating-leverage… | FY2026 adjusted EBITDA below $80m - below even the pre-raise guidance floor, breaking the operating-leverage inflection |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
BoxX-NoAF misses its 30-day post-operative AF endpoint at the H1 2027 readout. Removes the prophylactic-ablation market-expansion thesis (the deck's $7B+ cardiac-surgery opportunity rests on 'all cardiac surgery patients benefit from ablation + AtriClip', which the trial is designed to prove), strands the salesforce build management has said a positive readout funds, and casts doubt on LeAAPS (adjacent prophylactic hypothesis, undated readout). Not a valuation bear case: it removes the expansion mechanism.
Estimated probability 30%. No loss magnitude is on file, so the level at which the position would be resized cannot be struck and this case cannot be monitored against a loss budget.
Falsifiable and fundamental — not one of them is a price condition.
Scenario-weighted E[R] is -0.6% at spot (range -9.4% to -0.6% across constructions, sign negative in all) - below the 0.0 hurdle. For any holder, the upside-sell-discipline rung fires at the current price: trim or exit on valuation/opportunity cost. On approach to the $42.19 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | BoxX-NoAF misses its 30-day post-operative AF endpoint at the H1 2027 readout. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -1.8 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether the operating path today's price requires is achievable; the evidence does not settle it. The next evidence that should change the portfolio decision is the test dated 27 October 2026, or a daily close below $37.71, which forces an immediate review.